BR112017014090A2 - composição, e, métodos para produção de uma composição e estabilização de uma molécula de ácido nucleico. - Google Patents

composição, e, métodos para produção de uma composição e estabilização de uma molécula de ácido nucleico.

Info

Publication number
BR112017014090A2
BR112017014090A2 BR112017014090-0A BR112017014090A BR112017014090A2 BR 112017014090 A2 BR112017014090 A2 BR 112017014090A2 BR 112017014090 A BR112017014090 A BR 112017014090A BR 112017014090 A2 BR112017014090 A2 BR 112017014090A2
Authority
BR
Brazil
Prior art keywords
composition
nucleic acid
acid molecule
stabilizing
producing
Prior art date
Application number
BR112017014090-0A
Other languages
English (en)
Japanese (ja)
Inventor
Yamada Taimu
Toyofuku Hidekazu
Original Assignee
Bonac Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bonac Corporation filed Critical Bonac Corporation
Publication of BR112017014090A2 publication Critical patent/BR112017014090A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity

Abstract

a presente invenção provê uma composição que compreende uma molécula de ácido nucleico e uma solução tampão, dita composição sendo distinguida pelo fato de que (a) a composição está na forma de uma solução a temperatura ambiente e (b) o teor da molécula de ácido nucleico em uma composição após uma composição ser armazenada a 25ºc e uma umidade relativa de 60% por 4 semanas é 80% ou mais relativa àquela em uma composição no tempo de iniciação do armazenamento.
BR112017014090-0A 2014-12-29 2015-10-30 composição, e, métodos para produção de uma composição e estabilização de uma molécula de ácido nucleico. BR112017014090A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2014-267087 2014-12-29
JP2014267087 2014-12-29
JP2015081298 2015-04-10
JP2015-081298 2015-04-10
PCT/JP2015/080849 WO2016108264A1 (ja) 2014-12-29 2015-10-30 核酸分子を安定に含有する組成物

Publications (1)

Publication Number Publication Date
BR112017014090A2 true BR112017014090A2 (pt) 2018-03-06

Family

ID=56284418

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017014090-0A BR112017014090A2 (pt) 2014-12-29 2015-10-30 composição, e, métodos para produção de uma composição e estabilização de uma molécula de ácido nucleico.

Country Status (14)

Country Link
US (2) US20180036409A1 (pt)
EP (1) EP3241903A4 (pt)
JP (2) JP6462723B2 (pt)
KR (2) KR102585112B1 (pt)
CN (1) CN107208094A (pt)
AU (2) AU2015373071B2 (pt)
BR (1) BR112017014090A2 (pt)
CA (1) CA2971830A1 (pt)
HK (1) HK1244030A1 (pt)
IL (1) IL252905B (pt)
MX (1) MX2017008730A (pt)
RU (1) RU2723032C2 (pt)
SG (1) SG11201705312PA (pt)
WO (1) WO2016108264A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2714257C2 (ru) 2015-10-30 2020-02-13 Бонак Корпорейшн КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ В СТАБИЛЬНОМ СОСТОЯНИИ ОДНОЦЕПОЧЕЧНУЮ МОЛЕКУЛУ НУКЛЕИНОВОЙ КИСЛОТЫ, КОТОРАЯ ПОДАВЛЯЕТ ЭКСПРЕССИЮ ГЕНА TGF-β1
EP3532086A1 (fr) * 2016-10-27 2019-09-04 Selexel Nouvel oligonucleotide double brin bisquecifiques pour le traitement des cancers
FR3058061A1 (fr) * 2016-10-27 2018-05-04 Selexel Nouvelle utilisation d'oligonucleotides double brin
CN106857502A (zh) * 2017-03-03 2017-06-20 湖北新纵科病毒疾病工程技术有限公司 一种防止rna降解的样品保存液以及保存方法
TW201910514A (zh) 2017-07-28 2019-03-16 日商杏林製藥股份有限公司 纖維化治療劑
EP3696269A4 (en) 2017-10-13 2021-09-01 Bonac Corporation SINGLE STRAND NUCLEIC ACID MOLECULE AND ITS PRODUCTION PROCESS
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58102724A (ja) 1981-12-15 1983-06-18 Mitsubishi Chem Ind Ltd 防滑性ポリプロピレン成形品
DK0544713T3 (da) 1990-08-16 1997-09-29 Isis Pharmaceuticals Inc Oligonukleutider til modulering af virkningerne af cytomegalovirusinfektioner
ATE285239T1 (de) * 1996-04-26 2005-01-15 Merck & Co Inc Dna enthaltende impfstoffen
IL129497A0 (en) 1996-10-25 2000-02-29 Nexstar Pharmaceuticals Inc Vascular endothelial growth factor (vegf) nucleic acid ligand complexes
ZA99493B (en) * 1998-01-30 1999-07-22 Akzo Nobel Nv Method for the isolation of nucleic acid.
AU765177B2 (en) * 1998-03-13 2003-09-11 Wyeth Polynucleotide composition, method of preparation, and use thereof
DE19836559A1 (de) * 1998-08-12 2000-03-23 Antigen Gmbh Gefäß zur Entnahme von Blut
KR100718191B1 (ko) * 1999-12-02 2007-05-15 하이모 가부시키가이샤 전기영동용 폴리아크릴아미드프리캐스트겔, 그 제조방법및 그 겔을 사용한 전기영동법
JP3967516B2 (ja) * 2000-02-29 2007-08-29 ハイモ株式会社 Ｄｎａの電気泳動法
DE10006662A1 (de) * 2000-02-15 2001-08-23 Antigen Produktions Gmbh Gefäß zur Nukleinsäureanalytik
US20040058886A1 (en) * 2002-08-08 2004-03-25 Dharmacon, Inc. Short interfering RNAs having a hairpin structure containing a non-nucleotide loop
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
JP4782675B2 (ja) * 2003-06-18 2011-09-28 イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム ワクチン接種用スフィンゴイドポリアルキルアミン抱合体
BRPI0413907A (pt) * 2003-09-17 2006-10-24 Centelion método de preparação de plasmìdeo dna de grau farmacêutico
BRPI0515553A (pt) * 2004-09-17 2008-07-29 Centelion formulações lìquidas estáveis de dna de plasmìdeo
DE102005023170A1 (de) * 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
TW200808360A (en) * 2006-04-13 2008-02-16 Alcon Mfg Ltd RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
WO2009086558A1 (en) * 2008-01-02 2009-07-09 Tekmira Pharmaceuticals Corporation Improved compositions and methods for the delivery of nucleic acids
JP5608998B2 (ja) * 2009-03-31 2014-10-22 東洋紡株式会社 保存安定性に優れた核酸増幅検出試薬キット
US8691782B2 (en) * 2010-08-03 2014-04-08 Bonac Corporation Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
CA2824526C (en) * 2011-01-11 2020-07-07 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
JP6133883B2 (ja) * 2011-11-04 2017-05-24 日東電工株式会社 薬物送達用の脂質ナノ粒子の生成方法
ME03429B (me) * 2012-03-15 2020-01-20 Acraf Kationski polimeri na bazi glikogena
EP2846839B1 (en) * 2012-05-10 2019-02-20 Adynxx, Inc. Formulations for the delivery of active ingredients
CA2888286C (en) * 2013-03-06 2020-03-24 Biomics Biotechnologies Co., Ltd. Liposome formulation, its preparation and application

Also Published As

Publication number Publication date
KR102585112B1 (ko) 2023-10-10
RU2017126568A3 (pt) 2019-05-20
US20180036409A1 (en) 2018-02-08
EP3241903A1 (en) 2017-11-08
AU2015373071A1 (en) 2017-07-13
MX2017008730A (es) 2017-11-17
SG11201705312PA (en) 2017-07-28
WO2016108264A1 (ja) 2016-07-07
JPWO2016108264A1 (ja) 2017-08-31
RU2017126568A (ru) 2019-01-31
HK1244030A1 (zh) 2018-07-27
CN107208094A (zh) 2017-09-26
JP6462723B2 (ja) 2019-01-30
US20240016937A1 (en) 2024-01-18
EP3241903A4 (en) 2018-07-04
JP6808710B2 (ja) 2021-01-06
RU2723032C2 (ru) 2020-06-08
KR20220035404A (ko) 2022-03-22
IL252905A0 (en) 2017-08-31
IL252905B (en) 2020-09-30
KR20170094797A (ko) 2017-08-21
AU2015373071B2 (en) 2022-03-31
CA2971830A1 (en) 2016-07-07
JP2019077696A (ja) 2019-05-23
AU2022204391A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
BR112017014090A2 (pt) composição, e, métodos para produção de uma composição e estabilização de uma molécula de ácido nucleico.
BR112021024352A2 (pt) Composição de sachê de nicotina, produto de sachê de nicotina oral, e método para fabricar o produto de sachê de nicotina oral
BR112017027567A2 (pt) proteínas de fusão para inibir a angiogênese
BR112016015496A2 (pt) composição e processo para a produção da composição
CL2019002244A1 (es) Variantes de pertuzumab y su evaluación. (divisional solicitud 201702445)
PE20171238A1 (es) Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos
EA201691579A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
EA201891336A1 (ru) Гетероарилгидроксипиримидиноны в качестве агонистов рецептора apj
UY36949A (es) 2,4-dihidroxi-nicotinamidas como agonistas de apj
BR112018067995A2 (pt) composição oftalmológica
ECSP14030779A (es) Inhibidores del nampt
BR112018013504A2 (pt) método para desacetilação de biopolímeros
BR112017010445B8 (pt) Processo de produção de cristais de derivado de diazabiciclo-octano e preparação liofilizada estável
BR112017008680A2 (pt) composição de polímero transparente de poliamida modificada por impacto
UY37017A (es) Inhibidores aza-bencimidazol de pad4
UY36204A (es) Derivados de insoindolina.
BR112016008352A2 (pt) processo para a produção de polibutadienos catalisados com neodímio (ndbr), misturas de borracha que contêm polibutadienos catalisados com neodímio (ndbr), e usos de misturas de borracha
BR112017004797A2 (pt) película, processo para a fabricação de um laminado, e, laminado com uma camada de vidro frontal.
BR112016002573A2 (pt) método para a preparação de produtos à base de carne de músculo inteiro contendo óleo e produtos à base de carne reconstituída
BR112017013084A2 (pt) composições de polietileno com propriedades ópticas melhoradas
BR112016029158A2 (pt) composições de álcool poli-hídrico para desidratação de gás
BR112017022472A2 (pt) método para aumentar a porcentagem de anticorpo monomérico fab-dsfv espécies multiméricas
BR112016025160A2 (pt) método para preparar uma composição de aroma de reação, composição de aroma de reação, e, produto consumível
BR112017008551A2 (pt) processo para extrusão de polipropileno
CR20160494A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]